This website uses cookies to ensure that we give you the best experience on our website. Click here for more information.

ok
XGEVA (denosumab)

Terms of Use

The information contained in this site is for healthcare professionals only.

I am not a healthcare professional I confirm to be a healthcare professional
Treat with XGEVA®

XGEVA® (denosumab): SUBCUTANEOUS INJECTION FOR THE PREVENTION OF SKELETAL-RELATED EVENTS (SREs[SmPC, p. 2]

XGEVA® is administered as a simple, fixed dose, subcutaneous injection every four weeks in adults with bone metastases from solid tumours. XGEVA® should be administered under the responsibility of a healthcare professional.[SmPC, p. 2]

XGEVA® (DENOSUMAB) Product Specifics

XGEVA® is a sterile, preservative-free solution containing the active ingredient denosumab.[CHMP AR, p. 8]

learn more

XGEVA® (DENOSUMAB) METHOD OF ADMINISTRATION

XGEVA® is administered as a subcutaneous injection.[CHMP AR, p. 15]
 

learn more

XGEVA® (DENOSUMAB) Side Effects & Safety Information

The safety profile of XGEVA® has been studied extensively in a number of clinical studies.[SmPC, pp. 7-8]

learn more